Cryo-Cell International Receives NYSE American Continued Listing Notice: Key Details for Investors

Summary of Material Developments

• Cryo-Cell International, Inc. (NYSE American: CCEL) has received a notice of non-compliance from the NYSE American exchange regarding continued listing standards.
• The company currently has a stockholders’ deficit and has reported net losses in two of its three most recent fiscal years (FY 2023, 2024, and 2025).
• The listing of CCEL shares is not immediately affected; trading will continue while the company works on a compliance plan.
• Cryo-Cell must submit a plan to regain compliance within a prescribed timeframe. If accepted, up to 18 months may be granted to cure the deficiency.
• Failure to regain compliance or meet other listing standards could result in delisting proceedings against the company.

Detailed Analysis for Investors

Cryo-Cell International, Inc., the world’s first private cord blood bank and a leader in stem cell storage since 1992, announced that it has received a written notice from NYSE American stating that it is not in compliance with Section 1003(a) of the NYSE American Company Guide. This non-compliance stems from a reported stockholders’ deficit as of November 30, 2025, and net losses incurred in two of its three most recent fiscal years (ending November 30, 2023, 2024, and 2025).

Despite this notification, there is no immediate impact on the company’s listing status or the trading of its shares. CCEL shares will continue to be traded on the NYSE American under the same ticker while the company pursues a remediation plan.

As per NYSE American requirements, Cryo-Cell will submit a detailed plan to address the listing deficiencies within the required timeframe. If the exchange accepts the plan, the company may be granted up to 18 months from the date of the notice to restore compliance. During this period, compliance with all other listing requirements remains essential.

Shareholder Implications & Price-Sensitive Information:

• The company’s current financial condition—specifically, the stockholders’ deficit and recent operating losses—raises questions about its ongoing viability as a listed entity.
• If Cryo-Cell fails to regain compliance or meet other listing requirements, NYSE American could initiate delisting proceedings, which would severely impact the liquidity and marketability of CCEL shares.
• There is no assurance that the company will be successful in its compliance efforts, nor that the exchange will grant an extension.

Corporate Overview

Cryo-Cell International, founded in 1989, is a pioneer in cord blood and cord tissue banking, with over 500,000 clients from 87 countries. The company also operates a public banking program in partnership with Duke University, and its facility is FDA registered, cGMP-/cGTP-compliant, and licensed in all required states. It holds exclusive rights to the PrepaCyte-CB cord blood processing technology and has received several key industry accreditations.

Forward-Looking Statements and Risks

This announcement includes forward-looking statements about Cryo-Cell’s compliance plans and future prospects. Key risks include:

• Potential failure to execute its global expansion and product diversification strategies.
• Uncertainty regarding future profitability, especially with initiatives such as biopharmaceutical manufacturing and operating clinics.
• Dependence on successful R&D initiatives and collaborative partnerships.
• Risks related to the enforceability and revenue generation of their intellectual property and license agreements.
• Potential impact of public cord blood banking competition on core business.
• Complexities and uncertainties related to the potential spinoff of Celle Corp.

Investors should carefully consider these risks, as detailed in the company’s most recent Form 10-K.

Conclusion

The NYSE American non-compliance notice is a significant development for Cryo-Cell International and could materially affect the company’s share price and shareholder value. Investors should monitor the company’s compliance efforts and any further disclosures regarding its financial health and listing status.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information herein is based on public disclosures as of the date of publication and may be subject to change without notice.

View CRYO CELL INTERNATIONAL INC Historical chart here